Q-omics provides the consensus-scored TRAJ23 profile across patient tissues and cancer cell-line models. TRAJ23 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, TRAJ23 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, TRAJ23 RNA expression shows 13,051 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight CHOL, KIRC, and LSCC as cancer lineages where TRAJ23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAJ23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAJ23 survival associations across molecular data types. TRAJ23 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAJ23 RNA expression–survival associations across cancer types. High TRAJ23 expression shows unfavorable associations in CHOL, BLCA, PCPG and DLBC, but favorable associations in SKCM and CESC. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for TRAJ23 RNA expression.
This table summarizes TRAJ23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRAJ23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAJ23 shows lower tumor expression in THCA and higher tumor expression in KIRC, BRCA, LUSC, HNSC and STAD. The KIRC box plot shows higher TRAJ23 RNA expression in tumor versus normal tissue (log2 FC = +0.119, t-test p = .002).
This table shows molecular features associated with TRAJ23 in patient tissues and cancer cell lines. In patient samples, TRAJ23 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
